Dong Hang1,2, Ane Sørlie Kværner3, Wenjie Ma4, Yang Hu2, Fred K Tabung2, Hongmei Nan5, Zhibin Hu1, Hongbing Shen1, Lorelei A Mucci6, Andrew T Chan7,4,8,9, Edward L Giovannucci2,6,9, Mingyang Song2,6,4. 1. Department of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, China. 2. Department of Nutrition, Harvard TH Chan School of Public Health, Boston, MA. 3. Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway. 4. Clinical and Translational Epidemiology Unit and Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA. 5. Department of Epidemiology, Richard M Fairbanks School of Public Health, Indiana University, and Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN. 6. Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA. 7. Department of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, MA. 8. Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA. 9. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Abstract
BACKGROUND: Coffee consumption has been linked to lower risk of various health outcomes. However, the biological pathways mediating the associations remain poorly understood. OBJECTIVES: The aim of this study was to assess the association between coffee consumption and concentrations of plasma biomarkers in key metabolic and inflammatory pathways underlying common chronic diseases. METHODS: We investigated the associations of total, caffeinated, and decaffeinated coffee consumption with 14 plasma biomarkers, including C-peptide, insulin-like growth factor 1 (IGF-1), IGF binding protein (IGFBP) 1, IGFBP-3, estrone, total and free estradiol, total and free testosterone, sex hormone-binding globulin (SHBG), total adiponectin, high-molecular-weight (HMW) adiponectin, leptin, C-reactive protein (CRP), interleukin 6 (IL-6), and soluble tumor necrosis factor receptor 2 (sTNFR-2). Data were derived from 2 cohorts of 15,551 women (Nurses' Health Study) and 7397 men (Health Professionals Follow-Up Study), who provided detailed dietary data before blood draw and were free of diabetes, cardiovascular disease, or cancer at the time of blood draw. Multivariable linear regression was used to calculate the percentage difference of biomarker concentrations comparing coffee drinkers with nondrinkers, after adjusting for a variety of demographic, clinical, and lifestyle factors. RESULTS: Compared with nondrinkers, participants who drank ≥4 cups of total coffee/d had lower concentrations of C-peptide (-8.7%), IGFBP-3 (-2.2%), estrone (-6.4%), total estradiol (-5.7%), free estradiol (-8.1%), leptin (-6.4%), CRP (-16.6%), IL-6 (-8.1%), and sTNFR-2 (-5.8%) and higher concentrations of SHBG (5.0%), total testosterone (7.3% in women and 5.3% in men), total adiponectin (9.3%), and HMW adiponectin (17.2%). The results were largely similar for caffeinated and decaffeinated coffee. CONCLUSION: Our data indicate that coffee consumption is associated with favorable profiles of numerous biomarkers in key metabolic and inflammatory pathways. This trial was registered at clinicaltrials.gov as NCT03419455.
BACKGROUND: Coffee consumption has been linked to lower risk of various health outcomes. However, the biological pathways mediating the associations remain poorly understood. OBJECTIVES: The aim of this study was to assess the association between coffee consumption and concentrations of plasma biomarkers in key metabolic and inflammatory pathways underlying common chronic diseases. METHODS: We investigated the associations of total, caffeinated, and decaffeinated coffee consumption with 14 plasma biomarkers, including C-peptide, insulin-like growth factor 1 (IGF-1), IGF binding protein (IGFBP) 1, IGFBP-3, estrone, total and free estradiol, total and free testosterone, sex hormone-binding globulin (SHBG), total adiponectin, high-molecular-weight (HMW) adiponectin, leptin, C-reactive protein (CRP), interleukin 6 (IL-6), and soluble tumor necrosis factor receptor 2 (sTNFR-2). Data were derived from 2 cohorts of 15,551 women (Nurses' Health Study) and 7397 men (Health Professionals Follow-Up Study), who provided detailed dietary data before blood draw and were free of diabetes, cardiovascular disease, or cancer at the time of blood draw. Multivariable linear regression was used to calculate the percentage difference of biomarker concentrations comparing coffee drinkers with nondrinkers, after adjusting for a variety of demographic, clinical, and lifestyle factors. RESULTS: Compared with nondrinkers, participants who drank ≥4 cups of total coffee/d had lower concentrations of C-peptide (-8.7%), IGFBP-3 (-2.2%), estrone (-6.4%), total estradiol (-5.7%), free estradiol (-8.1%), leptin (-6.4%), CRP (-16.6%), IL-6 (-8.1%), and sTNFR-2 (-5.8%) and higher concentrations of SHBG (5.0%), total testosterone (7.3% in women and 5.3% in men), total adiponectin (9.3%), and HMW adiponectin (17.2%). The results were largely similar for caffeinated and decaffeinated coffee. CONCLUSION: Our data indicate that coffee consumption is associated with favorable profiles of numerous biomarkers in key metabolic and inflammatory pathways. This trial was registered at clinicaltrials.gov as NCT03419455.
Authors: Keming Yang; Michele R Forman; Patrick O Monahan; Brett H Graham; Andrew T Chan; Xuehong Zhang; Immaculata De Vivo; Edward L Giovannucci; Fred K Tabung; Hongmei Nan Journal: J Nutr Date: 2020-08-01 Impact factor: 4.798
Authors: Fred K Tabung; Liming Liang; Tianyi Huang; Raji Balasubramanian; Yibai Zhao; Paulette D Chandler; JoAnn E Manson; Elizabeth M Cespedes Feliciano; Kathleen M Hayden; Linda Van Horn; Clary B Clish; Edward L Giovannucci; Kathryn M Rexrode Journal: Clin Nutr Date: 2019-06-17 Impact factor: 7.324
Authors: Dong Hang; Oana A Zeleznik; Xiaosheng He; Marta Guasch-Ferre; Xia Jiang; Jun Li; Liming Liang; A Heather Eliassen; Clary B Clish; Andrew T Chan; Zhibin Hu; Hongbing Shen; Kathryn M Wilson; Lorelei A Mucci; Qi Sun; Frank B Hu; Walter C Willett; Edward L Giovannucci; Mingyang Song Journal: Diabetes Care Date: 2020-08-11 Impact factor: 19.112